Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients

Figure 2

Effects of LT₄ replacement therapy on prevalence of NAFLD and serum liver enzymes in mild SCH patients with dyslipidemia. (a) Prevalence of NAFLD for each group at baseline and end-of-study. (b–d) Changes in serum liver enzymes for each group. Data are presented as means. (b) Serum ALT at baseline and end-of-study. (c) Serum AST at baseline and end-of-study. (d) Reductions in AST during the course of study for each group. and for comparison between baseline and end-of-study, respectively. SCH: subclinical hypothyroidism; NAFLD: nonalcoholic fatty liver disease; LT₄: levothyroxine; ALT: alanine aminotransferase; AST: aspartate aminotransferase.

(a)

(b)

(c)

(d)